Table 2 Changes of BDNF levels and clinical characteristics across three genotypes in ANFE patients with schizophrenia.

From: The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study

Variable

Val/Val n = 58

Val/Met n = 112

Met/Met n = 55

F (p)

Baseline

Weight (kg)

60.9 ± 11.2

59.5 ± 12.3

57.8 ± 10.7

1.0 (0.37)

BMI (kg/m2)

21.8 ± 3.0

21.4 ± 3.7

21.0 ± 3.5

0.7 (0.50)

BDNF (ng)

9.0 ± 3.9

9.7 ± 3.5

9.7 ± 4.6

0.6 (0.56)

Age (yrs)

31.1 ± 10.2

26.9 ± 9.0

26.5 ± 8.2

5.0 (0.01)

Education (yrs)

9.0 ± 4.2

9.7 ± 3.7

8.8 ± 3.7

1.4 (0.25)

Onset age (yrs)

29.1 ± 10.4

25.4 ± 8.9

24.6 ± 7.9

4.3 (0.01)

Changes at 12-week follow-up

Weight gain (kg)

2.3 ± 3.4

2.6 ± 3.4

3.0 ± 4.5

0.5 (0.60)

BMI gain (kg/m2)

0.8 ± 1.2

1.0 ± 1.2

1.1 ± 1.6

0.4 (0.68)

BDNF levels (ng)

0.3 ± 4.3

0.4 ± 4.4

1.7 ± 9.7

0.7 (0.52)

PANSS total score

28.8 ± 21.1

23.3 ± 17.0

25.1 ± 18.3

1.6 (0.20)

P subscore

12.2 ± 7.1

9.7 ± 6.1

9.5 ± 6.3

3.2 (0.04)

N subscore

3.9 ± 7.3

4.2 ± 5.9

5.5 ± 5.7

1.0 (0.37)

G subscore

12.8 ± 10.5

9.6 ± 9.0

10.7 ± 9.5

2.0 (0.13)

  1. P subscore positive subscore, N subscore negative subscore, G subscore general psychopathology subscore.
Back to article page